2. Signaling Pathways
  3. GPCR/G Protein
  4. GPR84
  5. GPR84 Antagonist

GPR84 Antagonist

GPR84 Antagonists (8):

Cat. No. Product Name Effect Purity
  • HY-135303
    GLPG1205
    		Antagonist 99.64%
    GLPG1205 is potent, selective and orally active GPR84 (a G-protein-coupled receptor) antagonist with a favorable PK/PD profile. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis. GLPG1205 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-100775
    Fezagepras sodium
    		Antagonist 99.65%
    Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Fezagepras sodium decreases renal, liver and pancreatic fibrosis. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.
  • HY-112562
    GPR84 antagonist 8
    		Antagonist 99.93%
    GPR84 antagonist 8 is a selective GPR84 antagonist.
  • HY-161682
    GPR84 antagonist 9
    		Antagonist
    GPR84 antagonist 9 (compound 320) is an orally active GPR84 antagonist with the IC50 of 0.012 μM. GPR84 antagonist 9 can be used for study of inflammatory-driven pain diseases.
  • HY-151100
    GPR84 antagonist 3
    		Antagonist 99.54%
    GPR84 antagonist 3 (compound 42) is a potent GPR84 (G-protein-coupled receptor 84) antagonist. GPR84 antagonist 3 inhibits GTPγS, with a pIC50 of 8.28. GPR84 antagonist 3 has a favorable pharmacokinetic profile suitable.
  • HY-139675
    GPR84 antagonist 1
    		Antagonist 98.56%
    GPR84 antagonist 1 is a high affinity and highly selective competitive antagonist of human GPR84.
  • HY-145697
    GPR84 antagonist 2
    		Antagonist 99.53%
    GPR84 antagonist 2 (compound 33) is a potent, selective, and orally active GPR84 antagonist (IC50=8.95 nM). GPR84 antagonist 2 shows improved potency in the calcium mobilization assay and the ability to inhibit the chemotaxis of neutrophils and macrophages upon GPR84 activation. GPR84 antagonist 2 has the potential for the research of ulcerative colitis.
  • HY-100775A
    Fezagepras
    		Antagonist 99.38%
    Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Fezagepras decreases renal, liver and pancreatic fibrosis. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions.